Cirius Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-08.
Cirius Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 8, 2025. The filing reports $800K sold. Its industry group is Biotechnology. It names Robert Beardsley (Executive Officer), Jerry Callahan (Executive Officer), Michael Jandernoa (Director) (SEC Form D, October 8, 2025).
Is this your company?
Sell to companies like Cirius Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-08 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Cirius Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Cirius Therapeutics, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Cirius Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Cirius Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Cirius Therapeutics, Inc. →Get the full cited report on Cirius Therapeutics, Inc.
What the filing shows about Cirius Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cirius Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Cirius Therapeutics, Inc.'s address as 3133 Orchard Vista Dr. Sw, Grand Rapids, MI 49546.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Cirius Therapeutics, Inc. See pricing
Cirius Therapeutics, Inc. is a registered filer with the SEC (CIK 1702956) and has filed since 2024-08-20. 3 filings are on record, the latest on 2025-10-08.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Cirius Therapeutics, Inc.'s Form D of 2025-10-08 names Robert Beardsley, Jerry Callahan, Michael Jandernoa and 2 more as its officers, directors or promoters.
Its new offerings report $3.10M sold across 3 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Robert Beardsley is named as Executive Officer on the Form D that Cirius Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
Jerry Callahan is named as Executive Officer on the Form D that Cirius Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
Michael Jandernoa is named as Director on the Form D that Cirius Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
David Van Andel is named as Director on the Form D that Cirius Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
Robert Zerbe is named as Director on the Form D that Cirius Therapeutics, Inc. filed with the SEC on 8 October 2025, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2025-10-08 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Cirius Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cirius Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cirius Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cirius Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Cirius Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Cirius Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/cirius-therapeutics-inc-form-d-25000001